Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Completed × Lisaftoclax × Clear all

Phase

Status

Unknown 1 Recruiting 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Paclitaxel 291 Gemcitabine 254 Carboplatin 253 Cisplatin 249 Radiotherapy 218 Cyclophosphamide 215 Irinotecan 183 pembrolizumab 177 Docetaxel 171 Bevacizumab 166 Capecitabine 148 Nivolumab 141 Fluorouracil 132 Dexamethasone 124 Bortezomib 122 Oxaliplatin 115 Cytarabine 113 Erlotinib Hydrochloride 111 Sorafenib 110 Temozolomide 109 Doxorubicin 106 Rituximab 105 Leucovorin 105 Etoposide 104 Filgrastim 99 Everolimus 97 Lenalidomide 96 Ipilimumab 90 Pemetrexed 89 fludarabine phosphate 84

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡